Ryvu Therapeutics S.A. (FRA:9Y4)

Market Cap	98.87M -37.8%
Revenue (ttm)	20.57M +92.8%
Net Income	-20.62M
EPS	-0.89
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20
Open	4.070
Previous Close	4.155
Day's Range	4.070 - 4.070
52-Week Range	3.110 - 6.980
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 17, 2026

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally. The company’s lead candidate, Romaciclib (RVU120), is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat monotheraphy, combination therapy, monotherapy, and myelofibrosis. It also develops Dapolsertib (SEL24/MEN1703), a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Employees: 228
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 9Y4

Financial Performance

In 2025, Ryvu Therapeutics's revenue was 87.70 million, a decrease of -13.98% compared to the previous year's 101.96 million. Losses were -101.23 million, -9.16% less than in 2024.

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error